Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

No cookies to display.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

No cookies to display.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

No cookies to display.

Advancing Next-Generation Precision Therapies
Video Player

Immune, Inflammatory and Fibrotic Diseases

Represent a significant unmet need that can lead to chronic organ damage and dysfunction due to abnormal immune responses and persistent inflammation. These conditions often result in debilitating symptoms and a diminished quality of life for patients.

Video Player

Precision Medicine Approach

We anticipate leveraging advanced machine learning to identify patients with elevated PDE4 activity to enhance the responder population in our lead program targeting Ulcerative Colitis. By pinpointing key markers of colitis through RNA sequencing and meta-analysis, we hope to identify top PDE4-effector genes, which would enable us to predict potential patient responses to PDE4 inhibitors, ensuring targeting and effective treatment.

Development Programs

Differentiated prodrug candidates initially targeting established IBD market with potential to address shortcomings of existing therapies

PALI-2108

Indication
Ulcerative Colitis

Status
IND/CTA-Enabling

Highlights
IND/CTA-enabling tox studies completed and CTA submitted

Rapidly advancing towards first patient dosed in Phase 1 of healthy and UC patients in 2024

PALI-1908

Indication
Fibro Stenotic Crohn’s Disease

Status
Discovery

Highlights
Significant overlap with PALI-2108

POC for fibrosis pathway engagement completed

Press Releases

Mar 14, 2025Palisade Bio Commences Dosing in First Ulcerative Colitis Patient Cohort in Ongoing Phase 1a/b Study of PALI-2108
Positive preliminary data from all five single ascending dose (SAD) cohorts and ...
Mar 4, 2025Palisade Bio Participates in Virtual Investor "What This Means" Segment
Dr. Joerg Heyer, Head of Translational Science and Medicine of Palisade Bio high...

Sign up for Email Alerts

Stay up-to-date on our news, events and filings